bioMerieux SA BIM
EURONEXT · France · Health Technology
€77.55-0.20 (-0.26%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
BioMerieux SA (BMXMF) reports robust free cash flow growth and strategic product launches, while navigating regional market fluctuations and competitive pressures.
bioMérieux, a world leader in the field of in vitro diagnostics, today introduces the launch of GENE-UP® TYPER SLM, a new real-time PCR solution supporting rapid root cause analysis by discriminating Salmonella in the food industry environments.
The Saudi Arabia in vitro diagnostics (IVD) market is set for steady growth, driven by the increasing prevalence of chronic and infectious diseases and enhanced healthcare spending. Estimated to rise from US$ 820.36 million in 2025 to US$ 1.17 billion by 2034, the market is supported by technological advancements, governmental investments under Vision 2030, and a strong focus on early disease detection. Adoption of molecular diagnostics and automated systems is anticipated to fuel market demand,
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.